See how top analysts and institutions rate BLSH — including buy, hold, and sell recommendations.
| Rating Source | Action | Rating | Target Price | Updated |
|---|---|---|---|---|
| Keefe Bruyette | Initiated | Mkt Perform | $55 | 2025-09-15 |
| Deutsche Bank | Initiated | Hold | $51 | 2025-09-08 |
| Jefferies | Initiated | Hold | $49 | 2025-09-08 |
| Citigroup | Initiated | Buy | $66 | 2025-09-08 |
| Rosenblatt | Initiated | Buy | $60 | 2025-09-08 |
| Cantor Fitzgerald | Initiated | Overweight | $56 | 2025-09-08 |
| Canaccord Genuity | Initiated | Buy | $68 | 2025-09-08 |
| JP Morgan | Initiated | Neutral | $50 | 2025-09-08 |
| Bernstein | Initiated | Mkt Perform | $60 | 2025-09-08 |
| Compass Point | Initiated | Neutral | $45 | 2025-09-03 |
| Date | Strong Buy | Buy | Hold | Sell | Strong Sell |
|---|---|---|---|---|---|
| November 2025 | 0 | 4 | 7 | 0 | 0 |
| October 2025 | 0 | 4 | 7 | 0 | 0 |
The majority of institutional investors have issued a "Buy" rating for BLSH, and analyst sentiment aligns closely, with very few "Sell" recommendations. This suggests a broadly favorable outlook for the stock's performance.
